Rituximab to treat gemcitabine-induced hemolytic–uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review
详细信息 查看全文
- 作者：Georgia E. Ritchie ; Mangalee Fernando…
- 关键词：Gemcitabine ; Hemolytic–uremic syndrome ; Rituximab ; Pancreas adenocarcinoma
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：79
- 期：1
- 页码：1-7
- 全文大小：
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Oncology; Pharmacology/Toxicology; Cancer Research;
- 出版者：Springer Berlin Heidelberg
- ISSN：1432-0843
- 卷排序：79
文摘
PurposeHemolytic–uremic syndrome (HUS) is a rare side effect of gemcitabine, which is reported as having a high morbidity and mortality despite interventions with standard HUS therapies including plasmapheresis. The purpose of this report was to describe the successful treatment of gemcitabine-induced HUS (G-HUS) with rituximab. It also aims to summarize the literature regarding the morbidity and mortality of G-HUS in pancreatic adenocarcinoma depending on the treatment given, ultimately providing some guidance for beneficial therapies.